Last reviewed · How we verify

NCT00204269

Three-Year Trial on a New Testosterone Gel: Clinical Efficacy, Tolerability and Compliance

Status unknown Phase 3 Last updated 12 May 2006
What this trial tests

Phase 3 trial testing Testosterone Gel Wolff in Hypogonadism in 100 participants. Status unknown.

Timeline
1 January 2003
1 September 2006

Quick facts

Lead sponsorUniversity Hospital Muenster
PhasePhase 3
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment100
Start date1 January 2003
Estimated completion1 September 2006
Sites15 locations across Germany

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital Muenster

Who can join

18 and older, male only, with Hypogonadism. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The objective of the study is to examine the efficacy and tolerability of a three-year-Testosterone replacement therapy in hypogonadal patients as well as the patient's compliance. The replacement therapy will be performed with a new Testosterone Gel examined in previous trials as Testosteron Gel Wolff.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hypogonadism

Currently open trials in the same condition.

Other University Hospital Muenster trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00204269.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing